SELENOW and Alzheimer disease: Notably, our EWAS on cross-sectional and longitudinal changes in EM performance highlighted four genes, IRX2, SEPW1, HDC, and ITPK1, that were previously described in the context of other independent EWASs utilizing the AD case–control status and Braak stage as outcomes [34,42,43].